Clinical Trials

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06052306 2026-04-17

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

232 enrolled

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06402331 2026-04-08

AlphaBreak

110 enrolled

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06909825 2026-04-08

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

85 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT02044354 2026-04-01

CABA-DOC

Phase 3 Completed

195 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04853498 2026-03-31

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

Phase 1 Terminated

192 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06193486 2026-03-31

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Metastatic Castration-resistant Prostate Cancer

NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

162 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

12 enrolled

Phase 3 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

110 enrolled 12 charts

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04109729 2026-03-02

Rad2Nivo

39 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05125016 2026-02-27

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

370 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06533644 2026-02-27

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

70 enrolled

Phase 2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04754191 2026-02-12

ENCORE

34 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

60 enrolled

Phase 3 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT06492122 2026-01-29

ProTACT

50 enrolled

Phase 3 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Phase 1/2 Enrolling by invitation

Metastatic Castration-resistant Prostate Cancer

NCT05570994 2026-01-08

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

50 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06866938 2026-01-06

ReaLuP

58 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06155084 2025-12-22

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

84 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06228053 2025-12-22

SYNERGY-201

53 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06568562 2025-12-09

PRO-XL

32 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05682443 2025-12-02

PRESERVE-006

148 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06029998 2025-11-28

BORXPTEN

22 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06100705 2025-11-04

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

26 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05613894 2025-10-31

CaboLu

33 enrolled

Phase EARLY_PHASE1 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05603559 2025-10-03

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

NCT04158245 2025-09-22

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Phase 2 Completed

9 enrolled 14 charts

Phase 1/2 Not yet recruiting

Metastatic Castration-resistant Prostate Cancer

NCT07172126 2025-09-15

Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

291 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05544227 2025-07-23

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

15 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06383052 2025-05-21

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC

Metastatic Castration-resistant Prostate Cancer

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

13 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

NCT05340374 2025-04-06

LuCAB

35 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06250244 2024-12-11

177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Unknown

12 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04060394 2024-10-10

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Phase 1/2 Completed

49 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04629781 2024-08-01

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Phase 1 Terminated

11 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05613738 2024-07-10

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Phase NA Recruiting

9 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03770455 2024-07-09

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Phase 2 Terminated

8 enrolled 7 charts

Metastatic Castration-resistant Prostate Cancer

NCT05762536 2024-06-27

DAROTAXEL

245 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05458544 2024-04-29

LUCIDA

26 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03835533 2024-04-12

PORTER

Phase 1 Completed

43 enrolled 19 charts

Metastatic Castration-resistant Prostate Cancer

NCT05252364 2024-03-21

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

22 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05405439 2023-11-03

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled

387 enrolled 16 charts 2 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

Phase EARLY_PHASE1 Completed

Metastatic Castration-resistant Prostate Cancer

NCT05725070 2023-10-06

Phase 0/1 Study of 212Pb-NG001 in mCRPC

3 enrolled

Phase EARLY_PHASE1 Unknown

Metastatic Castration-resistant Prostate Cancer

NCT05558956 2023-07-27

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

100 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05955209 2023-07-21

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 2 Unknown

40 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04676607 2023-06-13

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2 Completed

6 enrolled